Freshfields Advises Terns Pharmaceuticals in $6.7bn Acquisition by Merck

Freshfields is advising Terns Pharmaceuticals, Inc., a clinical-stage oncology company, in its definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. Learn more about this transaction here.

The team is led by M&A partners Damien Zoubek and Jenny Hochenberg and includes counsel Zizi Petkova and associates Connor Smith, Esosa Asemota and Ryan Taylor. Partner Jeff Jay, senior associates Madeleine Tavcar and Christine Chong and associates Juliana Zhang, Wolfgang Paulson and Kayla Weston advised on life sciences and intellectual property matters; partner Nicole Foster, counsel Andrew Herman and associate Juan Pastor advised on employee compensation and benefits matters; partners Meghan Rissmiller and Stephanie Brown Cripps, counsel Elizabeth Suarez, senior associate William Cooke and associates Sandra Makeen and Jennifer King advised on antitrust and regulatory matters; and partner Steven Matays and associate HyunKyu Kim advised on tax matters.